These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 17468372)

  • 1. Clinical implications of the DREAM study: response to Davidson.
    Kanat M
    Diabetes Care; 2007 May; 30(5):e44; author reply e45. PubMed ID: 17468372
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical implications of the DREAM Study.
    Davidson MB
    Diabetes Care; 2007 Feb; 30(2):418-20. PubMed ID: 17259522
    [No Abstract]   [Full Text] [Related]  

  • 3. Research profile. Warding off type 2. Can taking glitazones cut the risk? Philip A. Kern, MD.
    Kordella T
    Diabetes Forecast; 2003 Jun; 56(6):113-5. PubMed ID: 15858895
    [No Abstract]   [Full Text] [Related]  

  • 4. More data needed on drug to delay the onset of diabetes.
    Comeau P
    CMAJ; 2006 Nov; 175(10):1192-3. PubMed ID: 17098942
    [No Abstract]   [Full Text] [Related]  

  • 5. Diabetes prevention: still no effective drugs.
    Prescrire Int; 2007 Dec; 16(92):258. PubMed ID: 18095391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of diabetes with rosiglitazone: Evidence of benefit or unexpected harm?
    Stulc T; Ceska R
    Med Hypotheses; 2008; 70(1):199-200. PubMed ID: 17855003
    [No Abstract]   [Full Text] [Related]  

  • 7. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal glucose tolerance in CF--when should we offer diabetes treatment?
    Moran A
    Pediatr Diabetes; 2009 May; 10(3):159-61. PubMed ID: 19422601
    [No Abstract]   [Full Text] [Related]  

  • 9. [Changed life style can prevent type 2 diabetes. Intervention studies show good results in "pre-diabetics"].
    Jansson S; Engfeldt P
    Lakartidningen; 2007 Dec; 104(49-50):3771-4. PubMed ID: 18214323
    [No Abstract]   [Full Text] [Related]  

  • 10. Glycaemic control and vascular complications in type 2 diabetes: new observations and clinical significance.
    Lebovitz HE
    J Indian Med Assoc; 2008 Nov; 106(11):724-6. PubMed ID: 19368098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Glitazones in type 2 diabetes--documented risks, uncertain benefits].
    Håkansson J
    Lakartidningen; 2007 Oct 24-30; 104(43):3198-200. PubMed ID: 18018937
    [No Abstract]   [Full Text] [Related]  

  • 12. [DREAM Study for prevention of diabetes. What conclusions may we draw?].
    Seissler J
    MMW Fortschr Med; 2006 Oct; 148(41):15. PubMed ID: 17190251
    [No Abstract]   [Full Text] [Related]  

  • 13. [Glitazones critically evaluated].
    Schernthaner G
    Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
    [No Abstract]   [Full Text] [Related]  

  • 14. [Glitazone - mailing no 1. In response to DMW 49/2007].
    Traut V
    Dtsch Med Wochenschr; 2008 Feb; 133(6):261; author reply 262-3. PubMed ID: 18236356
    [No Abstract]   [Full Text] [Related]  

  • 15. [Glitazone - mailing no 3. In response to DMW 49/2007].
    Gundel UF
    Dtsch Med Wochenschr; 2008 Feb; 133(6):261-2; author reply 262-3. PubMed ID: 18236354
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacologic treatment options for prediabetes.
    Hsueh WA; Handelsman Y
    Nat Clin Pract Endocrinol Metab; 2008 Jul; 4(7):380-1. PubMed ID: 18523427
    [No Abstract]   [Full Text] [Related]  

  • 17. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y; DeFronzo RA
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with type 2 diabetes.
    Kadoglou NP; Iliadis F; Liapis CD; Perrea D; Angelopoulou N; Alevizos M
    Diabetes Care; 2007 Sep; 30(9):2242-4. PubMed ID: 17586747
    [No Abstract]   [Full Text] [Related]  

  • 19. The rosiglitazone controversy: the Indian perspective.
    Mohan V; Joshi SR
    J Assoc Physicians India; 2007 Jul; 55():477-80. PubMed ID: 17907495
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
    ; Dagenais GR; Gerstein HC; Holman R; Budaj A; Escalante A; Hedner T; Keltai M; Lonn E; McFarlane S; McQueen M; Teo K; Sheridan P; Bosch J; Pogue J; Yusuf S
    Diabetes Care; 2008 May; 31(5):1007-14. PubMed ID: 18268075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.